rhodamine 123 has been researched along with cediranib in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, LM; Dai, CL; Fu, LW; Liang, YJ; Tao, LY; Wang, F; Yan, YY | 1 |
1 other study(ies) available for rhodamine 123 and cediranib
| Article | Year |
|---|---|
Cediranib (recentin, AZD2171) reverses ABCB1- and ABCC1-mediated multidrug resistance by inhibition of their transport function.
Topics: Adenosine Triphosphatases; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blotting, Western; Carrier Proteins; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Extracellular Signal-Regulated MAP Kinases; Flow Cytometry; Fluorescent Dyes; Humans; Indicators and Reagents; Multidrug Resistance-Associated Proteins; Oncogene Protein v-akt; Phosphorylation; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Rhodamine 123; RNA Interference; Tetrazolium Salts; Thiazoles | 2009 |